• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肥胖与心房颤动：综述

Obesity and Atrial Fibrillation: A Comprehensive Review.

作者信息

Na Jonathan, Garapati Sai Sita, Lador Adi

机构信息

Houston Methodist Hospital, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, US.

Division of Cardiac Electrophysiology, Houston Methodist Hospital, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, US.

出版信息

Methodist Debakey Cardiovasc J. 2025 Feb 18;21(2):35-43. doi: 10.14797/mdcvj.1516. eCollection 2025.

DOI:10.14797/mdcvj.1516
PMID:39990752
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11843930/
Abstract

Atrial fibrillation (AF) remains the most common arrhythmia worldwide, but its pathophysiology remains complex and multifactorial. As obesity has increased over the past couple of decades, much interest has been generated about its relationship with other diseases. As a result, the interplay between AF and obesity has been rigorously investigated as risk factor modification has become more important for the management of AF. In this review, we discuss the epidemiology of AF and obesity, the pathophysiology connecting these two diseases, and how obesity affects the management of AF.

摘要

心房颤动（AF）仍是全球最常见的心律失常，但其病理生理学仍然复杂且具有多因素性。在过去几十年中，随着肥胖率上升，人们对肥胖与其他疾病的关系产生了浓厚兴趣。因此，由于风险因素调整对房颤管理变得更为重要，房颤与肥胖之间的相互作用已得到深入研究。在本综述中，我们讨论房颤和肥胖的流行病学、连接这两种疾病的病理生理学，以及肥胖如何影响房颤的管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da1d/11843930/ae4e004ab400/mdcvj-21-2-1516-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da1d/11843930/ae4e004ab400/mdcvj-21-2-1516-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da1d/11843930/ae4e004ab400/mdcvj-21-2-1516-g1.jpg

相似文献

1
Obesity and Atrial Fibrillation: A Comprehensive Review.肥胖与心房颤动：综述
Methodist Debakey Cardiovasc J. 2025 Feb 18;21(2):35-43. doi: 10.14797/mdcvj.1516. eCollection 2025.
2
Disease-treatment interactions in the management of patients with obesity and diabetes who have atrial fibrillation: the potential mediating influence of epicardial adipose tissue.肥胖和糖尿病合并心房颤动患者管理中的疾病-治疗相互作用：心外膜脂肪组织的潜在中介影响。
Cardiovasc Diabetol. 2019 Sep 24;18(1):121. doi: 10.1186/s12933-019-0927-9.
3
Obesity and atrial fibrillation: Prevalence, pathogenesis, and prognosis.肥胖与心房颤动：患病率、发病机制和预后。
Prog Cardiovasc Dis. 2023 May-Jun;78:34-42. doi: 10.1016/j.pcad.2023.04.010. Epub 2023 Apr 28.
4
Obesity and Atrial Fibrillation Prevalence, Pathogenesis, and Prognosis: Effects of Weight Loss and Exercise.肥胖与心房颤动的患病率、发病机制和预后：体重减轻和运动的影响。
J Am Coll Cardiol. 2017 Oct 17;70(16):2022-2035. doi: 10.1016/j.jacc.2017.09.002.
5
Body mass and atrial fibrillation risk: Status of the epidemiology concerning the influence of fat versus lean body mass.体重与心房颤动风险：脂肪与瘦体重对其影响的流行病学现状。
Trends Cardiovasc Med. 2020 May;30(4):205-211. doi: 10.1016/j.tcm.2019.05.009. Epub 2019 May 31.
6
Impact of obesity on atrial fibrillation ablation.肥胖对心房颤动消融的影响。
Arch Cardiovasc Dis. 2020 Aug-Sep;113(8-9):551-563. doi: 10.1016/j.acvd.2020.03.023. Epub 2020 Aug 1.
7
Treatment of atrial fibrillation: a comprehensive review and practice guide.心房颤动的治疗：全面综述与实践指南
Cardiovasc J Afr. 2020;31(3):153-158. doi: 10.5830/CVJA-2019-064. Epub 2020 Mar 18.
8
Lifestyle modification in the prevention and treatment of atrial fibrillation.生活方式改变在心房颤动预防和治疗中的作用
Prog Cardiovasc Dis. 2015 Sep-Oct;58(2):117-25. doi: 10.1016/j.pcad.2015.07.001. Epub 2015 Jul 13.
9
PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study.减重和危险因素改善对心房颤动的预防和抑制作用：REVERSE-AF 研究。
Europace. 2018 Dec 1;20(12):1929-1935. doi: 10.1093/europace/euy117.
10
The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study.体重和糖尿病对新发心房颤动的影响：一项全国性基于人群的研究。
Cardiovasc Diabetol. 2019 Oct 1;18(1):128. doi: 10.1186/s12933-019-0932-z.

引用本文的文献

1
Integrated Advanced Echocardiographic and Biomarker Approach for the Early Detection of Atrial Cardiomyopathy in Middle-Aged Patients With Atrial Fibrillation.用于早期检测中年房颤患者心房心肌病的综合先进超声心动图和生物标志物方法
Cureus. 2025 Jul 24;17(7):e88642. doi: 10.7759/cureus.88642. eCollection 2025 Jul.

本文引用的文献

1
Integrating Genetic Insights, Technological Advancements, Screening, and Personalized Pharmacological Interventions in Childhood Obesity.整合儿童肥胖症的遗传见解、技术进步、筛查和个性化药物干预措施
Adv Ther. 2025 Jan;42(1):72-93. doi: 10.1007/s12325-024-03057-8. Epub 2024 Nov 13.
2
Effect of Obesity on the Use of Antiarrhythmics in Adults With Atrial Fibrillation: A Narrative Review.肥胖对心房颤动成人抗心律失常药物使用的影响：叙述性综述。
Clin Cardiol. 2024 Aug;47(8):e24336. doi: 10.1002/clc.24336.
3
Representation of obesity in contemporary atrial fibrillation ablation randomized controlled trials.
当代心房颤动消融随机对照试验中肥胖的代表性。
J Cardiovasc Electrophysiol. 2024 Oct;35(10):2006-2016. doi: 10.1111/jce.16396. Epub 2024 Aug 13.
4
Exploring Atrial Fibrillation: Understanding the Complex Relation Between Lifestyle and Genetic Factors.探索心房颤动：理解生活方式与遗传因素之间的复杂关系。
J Med Cases. 2024 Aug;15(8):186-194. doi: 10.14740/jmc4250. Epub 2024 Jul 25.
5
Atrial cardiomyopathy revisited-evolution of a concept: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS).心房心肌病再探——概念的演变：欧洲心脏病学会心律协会 (EHRA)、心律学会 (HRS)、亚太心律学会 (APHRS) 和拉丁美洲心律学会 (LAHRS) 的临床共识声明。
Europace. 2024 Aug 30;26(9). doi: 10.1093/europace/euae204.
6
Differences in the Impact of Obesity and Bariatric Surgery on Patients Hospitalized for Atrial Flutter and Atrial Fibrillation: A Nationwide Analysis, 2016-2020.肥胖症和减肥手术对因心房扑动和心房颤动住院患者影响的差异：2016 - 2020年全国性分析
Cureus. 2024 Jun 13;16(6):e62284. doi: 10.7759/cureus.62284. eCollection 2024 Jun.
7
Efficacy and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients (BMI ≥ 30 kg/m) with Atrial Fibrillation or Venous Thromboembolism: An Updated Systematic Review and Meta-Analysis.直接口服抗凝剂与华法林用于肥胖（体重指数≥30 kg/m²）房颤或静脉血栓栓塞患者的疗效及安全性：一项更新的系统评价和荟萃分析
J Clin Med. 2024 Jun 27;13(13):3784. doi: 10.3390/jcm13133784.
8
Catheter ablation of atrial fibrillation in "very severe" obese patients (BMI ≥ 40): Insights from "the ICE-Obese Extreme" study.“极度肥胖”患者（BMI≥40）心房颤动的导管消融：来自“ICE-肥胖极端”研究的见解。
J Cardiovasc Electrophysiol. 2024 Aug;35(8):1711-1713. doi: 10.1111/jce.16361. Epub 2024 Jul 4.
9
Efficacy and Safety of Non-Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation.非维生素 K 拮抗剂口服抗凝剂与华法林在整个体质量指数和体重范围内的疗效和安全性：一项对 4 项随机临床试验中房颤患者的个体患者数据的荟萃分析。
Circulation. 2024 Mar 19;149(12):932-943. doi: 10.1161/CIRCULATIONAHA.123.066279. Epub 2024 Jan 24.
10
Heart Failure with Preserved Ejection Fraction: The Pathophysiological Mechanisms behind the Clinical Phenotypes and the Therapeutic Approach.射血分数保留的心力衰竭：临床表型背后的病理生理机制及治疗方法。
Int J Mol Sci. 2024 Jan 8;25(2):794. doi: 10.3390/ijms25020794.